Omsättningen ökade på årsbasis men kassaflödet var svagt.
Kvartalet tyngs av minskad efterfrågan inom Supply Chain Solutions.
Redeye comments on Spago Nanomedical’s Q2 2023 report.
Redeye states that Nepa’s preliminary Q2 numbers were roughly in line with Redeye’s estimates, with ...
Redeye is encouraged by the news that Ireland is the first market to receive national approval for M...
Rapporten bekräftar vår syn Rapporten för det andra kvartalet var odramatisk och siffrorna kom in i ...
DT reports its Q2 results on Thursday, July 3rd. We expect the medical business to bring strong reve...
• Market is stabilising, yet uncertain • We lower our short- to medium-term assumptions • New perman...
Redeye is encouraged by the improved sales in Q2. Also, gross margins were at healthy levels of 30%,...
Incap is relatively confident about its full-year net sales development, despite inventory destockin...
• Q2e: We expect SEK 32.5m (+16%) sales and 9m EBIT (+64%) • Pre-released figures prove Q1 drop in s...
• One order and expected delivery in Q2 • Estimate reductions on low order intake, but volatility ex...
Net sales was close to consensus (Refinitiv) in Q2.
Redeye’s estimates are basically in line with reported numbers, when adjusting for non-recurring ite...
• 45% organic sales, 2.6% EBIT margin (ABGSCe 1.9%) • Guides for gradually improving margins in 2023...
Kontraktstillverkaren Hanza levererar ytterligare ett starkt kvartal där Huvudmarknader lyfter lönsa...
• Expect continued growth in Q2e, but some margin headwinds • Nordic EMS demand remains strong, but ...
Svag ARR-tillväxt, men stark marginal Omsättningen i kvartalet uppgick till 36,7 mkr, vilket motsvar...
• Q2'23 report due on Tuesday, 8 August • Revised oil price assumptions • P/NAV of 0.
Redeye updates its estimates on Safeture following the Q2 2023 report.
